Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM3 | Q14832 | 2/20 | 0.67 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.61 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4875386 | 0.88 | FOLH1 (0.51) | GRM3FOLH1NAALAD2 | |
| SCHEMBL20529841 | 0.83 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL5051325 | 0.83 | GRM3 (0.81) | GRM3FOLH1NAALAD2 | |
| SCHEMBL26830750 | 0.83 | GRM3 (0.65) | GRM3FOLH1NAALAD2 | |
| SCHEMBL25500315 | 0.82 | GRM3 (0.73) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1377526 | 0.82 | GRM3 (0.73) | GRM3FOLH1NAALAD2 | |
| SCHEMBL4135913 | 0.81 | GRM3 (1.00) | GRM3FOLH1NAALAD2 | |
| SCHEMBL14450542 | 0.81 | GRM3 (0.71) | GRM3FOLH1NAALAD2 | |
| SCHEMBL1374889 | 0.79 | GRM3 (0.69) | GRM3FOLH1NAALAD2 | |
| SCHEMBL14864542 | 0.79 | GRM3 (0.69) | GRM3FOLH1NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | UNIV YALE (US) | 2024-02-29 | — | — | US | disclosed |
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2023-08-15 | — | — | US | disclosed |
| US-10016412-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | UNIV YALE (US) | 2017-03-30 | — | — | US | disclosed |
| US-9556167-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | YALE UNIVERSITY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160347863-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2016-12-01 | — | — | US | disclosed |
| US-20160271156-A1 | ANTI-CANCER COMPOUNDS AND METHODS FOR TREATING CANCER | UNIV YALE (US) | 2016-09-22 | — | — | US | disclosed |
| US-9346846-B1 | Anti-cancer compounds and methods for treating cancer | YALE UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9296708-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2016-03-29 | — | — | US | disclosed |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-03-24 | — | — | US | disclosed |
| US-20150110742-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) | YALE UNIVERSITY (US) | 2015-04-23 | — | — | US | disclosed |
| US-8859509-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8852630-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2012-02-09 | — | — | US | disclosed |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | GRM3 922/4885FOLH1 56/4885NAALAD2 2674/4885 |
| US-10016412-B2 | TLR-agonist-conjugated antibody recruiting molecules (TLR-ARMs) | TLR3, TLR4, TLR1 | GRM3 66/4885FOLH1 148/4885NAALAD2 1795/4885 |
| US-20160082112-A1 | SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER | CD47, FCGR1A, FCGR2A | GRM3 54/4885FOLH1 12/4885NAALAD2 894/4885 |
| US-20120034295-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GRM3 922/4885FOLH1 56/4885NAALAD2 2674/4885 |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | TLR3, TLR4, TLR1 | GRM3 66/4885FOLH1 148/4885NAALAD2 1795/4885 |
| US-20160271156-A1 | ANTI-CANCER COMPOUNDS AND METHODS FOR TREATING CANCER | POLM, FOLR1, TYMP | GRM3 1535/4885FOLH1 37/4885NAALAD2 3115/4885 |
| US-20150110742-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMS) | TLR3, TLR4, TLR1 | GRM3 66/4885FOLH1 148/4885NAALAD2 1795/4885 |
| US-20110201563-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GRM3 922/4885FOLH1 56/4885NAALAD2 2674/4885 |
| US-20240067756-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GRM3 922/4885FOLH1 56/4885NAALAD2 2674/4885 |
| US-20160347863-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | GRM3 922/4885FOLH1 56/4885NAALAD2 2674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.